The Biovac Institute
South Africa
CHALLENGE
An Institute established through PPP between the South African government and a private health care company to set up a human vaccine manufacturer in South Africa. The company is the only vaccine manufacturing facility in sub-Saharan Africa, directly supporting the national health innovation strategy of the South African government.
SOLUTION
AMSCO provided assistance in sustaining operational capacity for the facility. We seconded senior managers in roles varying from Chief Operating Officer, Business Development Manager, Process & Qualification Engineer to Project Managers. The Insti- tute held several training programmes to build expertise in vaccine research and manu- facturing technology aimed at combating tuberculosis, malaria and HIV/AIDS. These included airflow filter particle training, validation quality management, and process engineering fundermentals.
IMPACTS
- Enhancement of local procurement. Currently Biovac has 273 local suppliers for products between US$10,000 - US$200Million.
- Training interventions built their commercial manufacturing capability.
- There was increased employment from 24 in 2003 to 154 in 2015.
.jpg)
